Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients외래 환자에서 중증 코로나19로의 진행을 예방하기 위한 조기 렘데시비르Randomized Controlled Trial Published on 2021-12-222022-09-25 Journal: The New England Journal of Medicine [Category] Fulltext, SARS, 신약개발, 임상, 진단, 치료제, [키워드] 95% CI 95% confidence interval Adverse adverse event age assigned Clinical outcome condition conducted coronavirus disease Course death Diabetes Mellitus died Disease progression dose double-blind efficacy end point end point EudraCT event hazard ratio high risk Hispanic Hospitalization hypertension IMPROVE Intravenous remdesivir Latinx lower risk Medical conditions obesity occurred Outpatient Patient patients hospitalized Placebo placebo-controlled trial Prevent progression randomization Randomized Randomly receive Remdesivir Result risk factor safety profile symptom onset symptomatic the patient the placebo group women [DOI] 10.1056/NEJMoa2116846 PMC 바로가기 [Article Type] Randomized Controlled Trial
Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort studyResearch Article Published on 2021-12-222022-10-28 Journal: BMC Infectious Diseases [Category] COVID-19, SARS, [키워드] 1:1 95% CI access acute respiratory syndrome administration Admission adverse event Analysis anti-cytokine therapy benefit cohort of patient cohort study comparable control group coronavirus COVID-19 demonstrated Dexamethasone discharge Effectiveness Fever Hospitalized hospitalized patient illness incidence Infection inhibitor initial Janus kinase laboratory parameter multicenter multiple comparison not different oxygen support Patient potential risk Program progression randomized trial recruited reduced reduction Registered Respiratory failure Result ruxolitinib safety profile SARS-CoV-2 supplementary material survival tested therapy Treatment was selected with COVID-19 [DOI] 10.1186/s12879-021-06982-z PMC 바로가기 [Article Type] Research Article
“World in motion” – emulsion adjuvants rising to meet the pandemic challengesReview Article Published on 2021-12-212022-10-04 Journal: NPJ Vaccines [Category] 비임상, [키워드] adaptive immune responses adjuvant adjuvants Administered antibody Antigen AS03 characterized clinical experience component cross-neutralizing defined dose draining lymph nodes Effectiveness Emulsion H1N1 influenza highlight human immunity immune response immune responses immunological responses induce Infectious diseases influenza vaccine injection long-lasting long-lived plasma cells mechanism mechanism of action memory B cells MF59 pandemic platform Population response rising safety profile SARS-CoV-2 pandemic Seasonal influenza T cell response Vaccine Vaccines variants Viral variants [DOI] 10.1038/s41541-021-00418-0 PMC 바로가기 [Article Type] Review Article
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study미국에서 Covid-19 회복기 혈장의 접근 및 안전성 확장 접근 프로그램 : 전국 레지스트리 연구Clinical Trial Published on 2021-12-202022-09-10 Journal: PLoS Medicine [Category] SARS, 신약개발, 임상, 진단, [키워드] 30-day mortality rate 95% CI access acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Administered affected age Analysis approval blood collection causative agent central institutional review board changes in characteristics of patient Clinical characteristics clinical trials convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 convalescent plasma demographic demographic and clinical characteristics demographic group demographic groups early stage early stages effective effort eligible patient Eligible patients Emerging infectious disease enrolled Enrollment Evidence example Expanded access Expanded Access Program Factor framework Hispanic ethnicity hospital Hospitalized hospitalized patient hospitalized patients incidence include Inclusion increases in Infection infection rate Infectious disease initiated institutional review board investigated investigator less life-threatening Local majority male Mayo Clinic Metrics mortality rate National obesity observational study Older overweight Patient plasma populations potential therapeutic agents Pragmatic progression provided public health public health emergency Racial randomized clinical trial Region regions registry data regulatory pathway regulatory pathways required researcher respiratory resulting risk Safe safety profile SARS-CoV-2 Serious Adverse Event Serious Adverse Events severe acute respiratory syndrome Coronavirus Spread Stage Study design Temporal the United State The United States therapy transfused transfusion Treatment treatment effects Trial registration United State United States website while widespread with COVID-19 [DOI] 10.1371/journal.pmed.1003872 PMC 바로가기 [Article Type] Clinical Trial
Physicians’ Experience with COVID-19 Vaccination: A Survey StudyArticle Published on 2021-12-172022-10-31 Journal: International journal for equity in health [Category] COVID-19, [키워드] addressed anonymously Anti-spike cascade checked Complete coronavirus COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccine cross-sectional cross-sectional survey Efficiency experience General population immunization Infection information Laboratory limit Lower moderate National outcome pandemic physician Physicians platform question questionnaire raise Re-infection reported Romania safety profile SARS-CoV2 setting severity Side effect Study participants survey the vaccine vaccination vaccination rate Vaccine vaccine dose Vaccine hesitancy with COVID-19 [DOI] 10.3390/healthcare9121746 PMC 바로가기 [Article Type] Article
A Case of Hepatotoxicity After Receiving a COVID-19 VaccineInternal Medicine Published on 2021-12-162022-10-31 Journal: Cureus [Category] COVID-19, [키워드] approved Case report clinical manifestation coronavirus disease COVID-19 COVID-19 vaccine COVID19 vaccine drug-induced drug-induced acute liver failure Efficacy Health hepatotoxicity Infection instances Patient patients who survived Pfizer receiving reported safety profile severe complication Side effect Vaccine vaccine side effects Vaccines [DOI] 10.7759/cureus.20455 PMC 바로가기 [Article Type] Internal Medicine
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adultsArticle Published on 2021-12-142022-10-04 Journal: Nature Communications [Category] SARS, 유전자 메커니즘, 임상, 치료법, [키워드] Adults adverse event age antibody BNT162b2 BNT162b2 vaccine COVID-19 vaccine dose doses evaluate event geometric geometric mean titer groups healthy immune response individual interim analysis Intramuscular injection Japanese local reaction Mild moderate Neutralizing of BNT162b2 Older age participant Phase I trials Placebo Randomized randomized study receive recipient RNA vaccines robust safety profile SARS-CoV-2 second dose Serious Adverse Event Serious Adverse Events serum stratified [DOI] 10.1038/s41467-021-27316-2 PMC 바로가기 [Article Type] Article
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents청소년의 mRNA-1273 SARS-CoV-2 백신 평가Clinical Trial Published on 2021-12-092022-09-12 Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 진단, [키워드] 95% CI 95% confidence interval absolute difference acute respiratory syndrome Administered Adolescent Adults Adverse reaction age assigned Asymptomatic coronavirus coronavirus disease criterion development Efficacy fatigue geometric mean titer headache healthy immune response incidence Infection injection Injection-site pain Moderna mRNA-1273 mRNA-1273 vaccine occurred participant Participants phase 3 trial Placebo placebo-controlled trial pseudovirus neutralizing antibody Randomly receive reported safety profile SARS-CoV-2 Secondary objective Serious Adverse Event Serologic response the placebo group the vaccine [DOI] 10.1056/NEJMoa2109522 PMC 바로가기 [Article Type] Clinical Trial
Strategies for drug repurposing against coronavirus targetsCOVID-19 therapy edited by Isabella Zanella & Simon Pitchford Published on 2021-12-042022-10-04 Journal: Current Research in Pharmacology and Drug Discovery [Category] 신약개발, [키워드] agency approved drug ARDS attrition Compound coronavirus coronavirus target de novo drug Drug discovery Drug repurposing Epidemic hospital human coronaviruses Impact in silico screening in viral involved MERS-CoV pandemic Patient Proteases public health Regulatory repurposing safety profile SARS-CoV SARS-CoV-2 significantly Strategy target Treatment viral replication viral-induced virus widespread [DOI] 10.1016/j.crphar.2021.100072 PMC 바로가기 [Article Type] COVID-19 therapy edited by Isabella Zanella & Simon Pitchford
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trialResearch article Published on 2021-12-012022-10-05 Journal: The Lancet Regional Health - Americas [Category] 유전자 메커니즘, 임상, [키워드] adverse event Anti-RBD antibody Antibody titre Asymptomatic baseline booster cellular response clinical clinical trial convalescent COVID-19 Cuba dimeric elicited ELISA ENhance Environment evaluated finding funding greater Humoral response IFN-γ IgG increase in individual inhibitory Intramuscular injection Local median Mild minor natural immunity neutralization Open-label Partial Participants PCR-positive Primary outcome producing Public reactogenicity Receptor binding domain registry Reinfection reported safety profile SARS-CoV-2 Science secondary outcome Serious Adverse Event single dose subclinical infection T cell technology TNF-α vaccination Vaccine vaccine immunogenicity Virus neutralization titre [DOI] 10.1016/j.lana.2021.100079 [Article Type] Research article